La escasez de medicamentos contra el cáncer persiste en EE.UU.
VIERNES , 6 de octubre de 2023 (HealthDay News) — Los centros contra el cáncer en EE.UU. continúan enfrentando la escasez de medicamentos de quimioterapia más utilizados, de acuerdo con una nueva encuesta, aunque el problema es menor al registrado e…
Learn MoreNCCN: Cancer Centers Still Experiencing Shortages of Chemo Drugs
THURSDAY, Oct. 5, 2023 (HealthDay News) — Many cancer centers are still experiencing a shortage of carboplatin, cisplatin, and other chemotherapy drugs, according to the results of a follow-up survey conducted Sept. 6 to 20, 2023, by the National Com…
Learn MoreCancer Drug Shortages Persist Across U.S.
THURSDAY, Oct. 5, 2023 (HealthDay News) — U.S. cancer centers continue to have shortages of commonly used chemotherapy drugs, a new survey shows, though the medications are not as scarce as they were last June.The National Comprehensive Cancer Networ…
Learn MoreGemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published online Oct. 2 in Nature Medicine.
Matthew D. Galsky, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a phase 2 study of 76 patients with MIBC who received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients who achieved a clinical complete response (cCR) could proceed without cystectomy.
Of the patients, 33 achieved a cCR (43 percent); 32 of the 33 opted to forgo immediate cystectomy. The researchers found that the positive predictive value of cCR for a composite outcome of two-year metastasis-free survival in patients forgoing immediate cystectomy or ATM, RB1, FANCC, and ERCC2) or increased tumor mutational burden. There was an association noted between the baseline and on-treatment immune contexture with clinical outcomes.
“Treatment for muscle-invasive bladder cancer is in need of major improvements from both a quality-of-life and an effectiveness standpoint,” Galsky said in a statement. “If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer.”
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Learn MoreSubsequent Breast Cancer Risk Higher for Child Cancer Survivors Receiving Doxorubicin
TUESDAY, Sept. 19, 2023 (HealthDay News) — For female survivors of childhood cancer, the risk for subsequent breast cancer (SBC) is more than twofold higher for those who receive a cumulative dose of 200 mg/m² or more of doxorubicin compared with tho…
Learn MoreDiet, Exercise Intervention May Aid Chemotherapy Outcomes in Breast Cancer
FRIDAY, Sept. 15, 2023 (HealthDay News) — A home-based diet and exercise intervention could improve outcomes for women undergoing chemotherapy for breast cancer, according to a study published online Sept. 1 in the Journal of Clinical Oncology.Tara S…
Learn MoreA Beginner’s Guide to Understanding Cancer Treatment Options
If you or a loved one has received a cancer diagnosis, you’re not alone. With approximately 1.9 million new cancer cases diagnosed annually, according to the American Cancer Society, that’s roughly 5,250 new cases every day in the United States.And af…
Learn MoreThe Most Common Chemotherapy Side Effects (& How to Help Minimize Them)
As the number of cancer survivors continues to rise in the United States, thanks to population growth, aging and advances in early detection and treatment, it’s important to understand the challenges they face during and after cancer therapy.Chemother…
Learn MoreFewer Complications Seen With Vitamin C, D Supplementation in AML
WEDNESDAY, Sept. 6, 2023 (HealthDay News) — For patients with acute myeloid leukemia (AML), supplementation with vitamins C and D during chemotherapy may improve outcomes but may not improve overall survival (OS), according to a study published onlin…
Learn MoreRisks for MDS/Leukemia Increased for Survivors of Common Lymphoid Neoplasms
THURSDAY, Aug. 17, 2023 (HealthDay News) — Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, accordin…
Learn More